T315I clone selection in a Ph+ all patient under low-dose ponatinib maintenance.
Details
State: Public
Version: Final published version
Serval ID
serval:BIB_F5940E9F0C9D
Type
Article: article from journal or magazin.
Publication sub-type
Case report (case report): feedback on an observation with a short commentary.
Collection
Publications
Institution
Title
T315I clone selection in a Ph+ all patient under low-dose ponatinib maintenance.
Journal
Clinical case reports
ISSN
2050-0904 (Print)
ISSN-L
2050-0904
Publication state
Published
Issued date
08/2017
Peer-reviewed
Oui
Volume
5
Number
8
Pages
1320-1322
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Publication Status: epublish
Abstract
We report here the clinical course of a Ph+ ALL patient who was treated with ponatinib 15 mg/day, as maintenance therapy, and developed a BCR-ABL T315I mutation leading to ALL relapse. This clonal evolution was reversed, without adverse effects, by increasing ponatinib to 45 mg/day. To our knowledge, we have been confronted with the first clinical case of a T315I clonal selection of ALL caused by subeffective therapeutic level of the drug. This single patient experience highlights the risk of T315I clone selection in Ph+ ALL treated with reduced dose ponatinib.
Keywords
Acute lymphoblastic leukemia, T315I BCR‐ABL, treatment maintenance, tyrosine kinase inhibitor
Pubmed
Web of science
Open Access
Yes
Create date
05/09/2017 16:21
Last modification date
09/01/2024 13:45
Usage data
